{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T01:24:05Z","timestamp":1773365045094,"version":"3.50.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,5]],"date-time":"2021-12-05T00:00:00Z","timestamp":1638662400000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Mol Allergy"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Asthma, and severe asthma in particular, is often managed within a specialized field with allergists and clinical immunologists playing a leading role. In this respect, the National Scientific Society SIAAIC (<jats:italic>Societ\u00e0 Italiana di Allergologia, Asma ed Immunologia Clinica<\/jats:italic>), structured in Regional and Inter-Regional sections, interviewed a large number of specialists involved in the management of this respiratory disease.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A survey entitled \u201cManagement of patients with asthma and severe asthma\u201d based on 17 questions was conducted through the SIAAIC newsletter in 2019 thanks to the collaboration between GlaxoSmithKline S.p.A. and the Inter-Regional Section of SIAAIC of Central Italy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Fifty-nine allergists and clinical immunologists participated to the survey, and 40 of them completed the entire questionnaire. Almost all of the specialists (88%) reported that asthma control was achieved in above 50% of their patients, even if only one third (32%) actually used validated clinical tools such as asthma control test (ACT). Poor adherence to inhaled therapy was recognized as the main cause of asthma control failure by 60% of respondents, and 2\u20135\u00a0min on average is dedicated to the patient inhaler technique training by two-thirds of the experts (65%). Maintenance and as-needed therapy (SMART\/MART) is considered an appropriate approach in only a minority of the patients (25%) by one half of the respondents (52%). A high number of exacerbations despite the maximum inhalation therapy were recognized as highly suspicious of severe asthma. Patients eligible for biological therapies are 3\u20135% of the patients, and almost all the responders (95%) agreed that patients affected by severe asthma need to be managed in specialized centers with dedicated settings. Biological drugs are generally prescribed after 3\u20136\u00a0months from the initial access to the center, and once started, the follow-up is initially programmed monthly, and then every 3\u20136\u00a0months after the first year of treatment (96% of responders). After phenotyping and severity assessment, comorbidities (urticaria, chronic rhinosinusitis with or without nasal polyps, vasculitis, etc.) are the drivers of choice among the different biological drugs. In the management of severe asthma, general practitioners (GPs) should play a central role in selecting patients and referring them to specialized centers while Scientific Societies should train GPs to appropriately recognize difficult asthma and promote public disease awareness campaigns.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This survey which collects the point of view of allergists and clinical immunologists from Central Italy highlights that asthma control is still not measured with validated instruments. There is a general consensus that severe asthma should be managed only in dedicated centers and to this aim it is essential to encourage patient selection from a primary care setting and develop disease awareness campaigns for patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12948-021-00160-x","type":"journal-article","created":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T05:02:51Z","timestamp":1638766971000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Management of patients with severe asthma: results from a survey among allergists and clinical immunologists of the Central Italy Inter-Regional Section of SIAAIC"],"prefix":"10.1186","volume":"19","author":[{"given":"G.","family":"Carli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Farsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Bormioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Ridolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Fassio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Pucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Montevecchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Riparbelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Cosmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9184-5089","authenticated-orcid":false,"given":"P.","family":"Parronchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,12,5]]},"reference":[{"key":"160_CR1","unstructured":"GINA. 2019. https:\/\/ginasma.it\/wp-content\/uploads\/materiali\/2019\/GINA_report_ita_2019.pdf."},{"key":"160_CR2","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3389\/fped.2019.00054","volume":"7","author":"M Gallucci","year":"2019","unstructured":"Gallucci M, Carbonara P, Pacilli AMG, Di Palmo E, Ricci G, Nava S. Use of symptoms scores, spirometry, and other pulmonary function testing for asthma monitoring. Front Pediatr. 2019;7:54. https:\/\/doi.org\/10.3389\/fped.2019.00054.","journal-title":"Front Pediatr"},{"key":"160_CR3","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1183\/09031936.00075614","volume":"45","author":"M Engelkes","year":"2015","unstructured":"Engelkes M, Janssens HM, de Jongste JC, Sturkenboom MCJM, Verhamme KMC. Medication adherence and the risk of severe asthma exacerbations: a systematic review. Eur Respir J. 2015;45:396\u2013407. https:\/\/doi.org\/10.1183\/09031936.00075614.","journal-title":"Eur Respir J"},{"key":"160_CR4","unstructured":"Report OSMED. 2019. https:\/\/www.aifa.gov.it\/documents\/20142\/1205984\/rapporto-osmed-2019.pdf\/f41e53a4-710a-7f75-4257-404647d0fe1e."},{"key":"160_CR5","unstructured":"https:\/\/www.aaaai.org\/conditions-and-treatments\/library\/allergy-library\/nasal-polyps."},{"issue":"6","key":"160_CR6","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1111\/coa.12189","volume":"38","author":"B Large","year":"2013","unstructured":"Large B, Holst R, Thilsing T, Baelum J, Kjeldsent A. Quality of life and associated factors in persons with chronic rhinosinusitis in the general population: a prospective questionnaire and clinical cross-sectional study. Clin Otorinol. 2013;38(6):474\u201380. https:\/\/doi.org\/10.1111\/coa.12189.","journal-title":"Clin Otorinol"},{"key":"160_CR7","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1710-1492-9-8","volume":"9","author":"AJ Hamdan","year":"2013","unstructured":"Hamdan AJ, Ahmed A, Abdullah AH, Khan M, Baharoon S, Salih SB, Halwani R, Al-Muhsen S. Improper inhaler technique is associated with poor asthma control and frequent emergency department visits. Allergy Asthma Clin Immunol. 2013;9:8. https:\/\/doi.org\/10.1186\/1710-1492-9-8.","journal-title":"Allergy Asthma Clin Immunol"},{"key":"160_CR8","doi-asserted-by":"publisher","first-page":"429","DOI":"10.3109\/02770903.2013.871558","volume":"51","author":"S Baddar","year":"2014","unstructured":"Baddar S, Jayakrishnan B, Al-Rawas OA. Asthma control: importance of compliance and inhaler technique assessments. J Asthma. 2014;51:429\u201334. https:\/\/doi.org\/10.3109\/02770903.2013.871558.","journal-title":"J Asthma"},{"key":"160_CR9","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1183\/09031936.99.14510349","volume":"14","author":"J van der Palen","year":"1999","unstructured":"van der Palen J, Klein JJ, van Herwaarden CLA, Zielhuis GA, Seydel ER. Multiple inhalers confuse asthma patients. Eur Respir J. 1999;14:1034\u20137. https:\/\/doi.org\/10.1183\/09031936.99.14510349.","journal-title":"Eur Respir J"},{"key":"160_CR10","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1016\/j.rmed.2011.07.004","volume":"105","author":"V Giraud","year":"2011","unstructured":"Giraud V, Allaert F-A, Roche N. Inhaler technique and asthma: feasability and acceptability of training by pharmacists. Respir Med. 2011;105:1815\u201322. https:\/\/doi.org\/10.1016\/j.rmed.2011.07.004.","journal-title":"Respir Med"},{"key":"160_CR11","doi-asserted-by":"publisher","first-page":"100464","DOI":"10.1016\/j.waojou.2020.100464","volume":"13","author":"GW Canonica","year":"2020","unstructured":"Canonica GW, et al. Oral CorticoSteroid sparing with biologics in severe asthma: a remark of the Severe Asthma Network in Italy (SANI). World Allergy Organ J. 2020;13:100464. https:\/\/doi.org\/10.1016\/j.waojou.2020.100464.","journal-title":"World Allergy Organ J"},{"issue":"2","key":"160_CR12","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/all.13556","volume":"74","author":"J Voorham","year":"2019","unstructured":"Voorham J, Xiao Xu, Price DB, Golam S, Davis J, Ling JZJ, Kerkhof M, Ow M, Tran TN. Healthcare resource utilization and costs associated with incremental systemic corticosteroid exposure in asthma. Allergy. 2019;74(2):273\u201383. https:\/\/doi.org\/10.1111\/all.13556.","journal-title":"Allergy"},{"key":"160_CR13","unstructured":"Diagnosis and management of difficult-to-treat and severe asthma\u00a9 GINA; 2019. https:\/\/ginasthma.org\/severeasthma\/."},{"issue":"2","key":"160_CR14","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1080\/02770903.2017.1322611","volume":"55","author":"FC Albers","year":"2018","unstructured":"Albers FC, M\u00fcllerov\u00e1 H, Gunsoy NB, Shin J-Y, Nelsen LM, Bradford ES, Cockle SM, Suruki RY. Biologic treatment eligibility for real-world patients with severe asthma: the IDEAL study. J Asthma. 2018;55(2):152\u201360. https:\/\/doi.org\/10.1080\/02770903.2017.1322611.","journal-title":"J Asthma"}],"container-title":["Clinical and Molecular Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12948-021-00160-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12948-021-00160-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12948-021-00160-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T05:03:07Z","timestamp":1638766987000},"score":1,"resource":{"primary":{"URL":"https:\/\/clinicalmolecularallergy.biomedcentral.com\/articles\/10.1186\/s12948-021-00160-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["160"],"URL":"https:\/\/doi.org\/10.1186\/s12948-021-00160-x","relation":{},"ISSN":["1476-7961"],"issn-type":[{"value":"1476-7961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"31 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Bormioli S. has received a fellowship from GSK; Riparbelli M. is a employee of the GSK group; Montevecchi M., is a former GSK employee; Cosmi L. has been consultant and speaker of GSK; Parronchi P. has been consultant and speaker of GSK; Rossi O. has been speaker of GSK. Carli G., Farsi A., Ridolo E., Fassio F., and Pucci S. declare no COI.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22"}}